The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS
- Conditions
- HIV InfectionsMycobacterium Avium-intracellular Infection
- Registration Number
- NCT00002331
- Lead Sponsor
- Abbott
- Brief Summary
PRIMARY: To assess the tolerability of the combination regimen of clarithromycin plus ethambutol with or without clofazimine in patients with disseminated Mycobacterium avium Complex (dMAC).
SECONDARY: To determine the proportion of patients achieving a sterile blood culture along with the time required to achieve it. To determine the duration of bacteriological response, defined as length of time that blood cultures remain sterile.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (17)
Kaiser Permanente Med Ctr
🇺🇸San Francisco, California, United States
UCD Med Ctr
🇺🇸Sacramento, California, United States
Santa Clara Valley Med Ctr
🇺🇸San Jose, California, United States
George Washington Univ Med Ctr
🇺🇸Washington, District of Columbia, United States
Dr Margaret Fischel
🇺🇸Miami, Florida, United States
Saint Joseph's Hosp / Infectious Disease Rsch Institute
🇺🇸Tampa, Florida, United States
Rush Presbyterian - Saint Luke's Med Ctr
🇺🇸Chicago, Illinois, United States
Tulane Univ Med School
🇺🇸New Orleans, Louisiana, United States
Johns Hopkins Univ School of Medicine
🇺🇸Baltimore, Maryland, United States
Beth Israel Med Ctr
🇺🇸New York, New York, United States
Scroll for more (7 remaining)Kaiser Permanente Med Ctr🇺🇸San Francisco, California, United States